Skip to main content

Table 2 Efficacy of a single oral dose of a novel chewable tablet (Simparica Trio™) containing sarolaner, moxidectin, and pyrantel pamoate against induced adult Ancylostoma caninum and adult Uncinaria stenocephala infections in dogs

From: Efficacy of Simparica Trio™, a novel chewable tablet containing sarolaner, moxidectin and pyrantel, against induced hookworm infections in dogs

StudySpecies (isolate origin)Stage at time of treatmentDay of inoculationaDay of treatmentDay of worm recoveryTreatment groupbnNo. of infected dogsWorm count rangeGeometric mean worm countEfficacy compared to placebo
% EfficacyTest statistic
5A. caninum
(Europe)
Adult− 3307Placebo8859–136109.9
Simparica Trio™8000.0100%t(7) = 47.61
P < 0.0001
6A. caninum
(USA)
Adult− 32Placebo889–4622.7
Simparica Trio™8000.0100%t(7) = 20.55
P < 0.0001
7U. stenocephala
(Europe)
Adult− 3207Placebo88246–545390.1
Simparica Trio™8000.0100%t(7) = 68.90
P < 0.0001
8U. stenocephala
(Europe)
AdultPlacebo88253–935537.8
Simparica Trio™8000.0100%t(7) = 46.56
P < 0.0001
  1. aIn studies 5 and 6, each dog was inoculated with 200 ± 50 L3 A. caninum and in Studies 7 and 8 each dog was inoculated with 1250 ± 50 L3 U. stenocephala
  2. bSimparica Trio™ provided minimum dosages of 1.2 mg/kg sarolaner, 24 µg/kg moxidectin, and 5 mg/kg pyrantel (as pamoate salt)
  3. Abbreviation: n, number of animals per group